Additional Services
Genetic studies, sex selection, stem cells, international sperm bank. Complementary technologies that add to your fertility plan to boost the outcome.
Additional Services are complementary technologies that integrate into your fertility plan when the case requires it. They do not replace the main treatment: they enhance it with genetics, regenerative medicine, advanced diagnosis or access to international gametes.
Their purpose is clear: make decisions with more information, select genetically fit embryos, optimize the biological environment before transfer, and expand options when own resources are not enough.
At Ingenes we apply them as part of the TripleMed™ model, integrating reproductive medicine, genetic and regenerative medicine, and metabolic medicine in one personalized plan.
- 0+ Complementary technologies
- +0 Years applying them
- 0% Effectiveness of Eligender™
Three ways to enhance your treatment
-
Genetic selection before transfer
PGT-A and PGT-M allow studying embryo DNA before transfer. Only embryos with chromosomal integrity, or that do not carry the specific hereditary disease being avoided, are transferred.
-
Biological environment optimization
Procelk™ with exosomes and the Implantation Score improve gamete quality and predict the most receptive moment of the endometrium. Biology stops being an unknown.
-
Informed decisions with data
Eligender™ allows selecting the baby's sex when medically indicated. Clarix™ detects genetic alterations during pregnancy non-invasively. Every step is decided with evidence.
Which complementary technologies we offer
-
Genetic Test PGT-A
Embryonic DNA study to detect aneuploidies (alterations in chromosome number) before transfer. Indicated in advanced reproductive age, recurrent losses, and implantation failures.
See PGT-A -
Eligender™ · Sex Selection
Allows choosing the baby's sex with 99% effectiveness. Indicated when there are genetic diseases linked to sex chromosomes or by informed family decision.
See Eligender™ -
Implantation Score
Non-invasive study that evaluates egg quality and identifies embryos with the greatest implantation potential. Ideal when ovarian quality is limited.
See Score -
Prenatal Test Clarix™
Non-invasive prenatal diagnosis from a maternal blood sample. Detects chromosomal alterations during pregnancy without risk to the baby.
See Clarix™ -
Procelk™ · Stem Cells
Application of stem-cell-derived exosomes to enhance gamete and embryo quality. Adds regenerative medicine to the IVF cycle.
See Procelk™ -
International Sperm Bank
Access to donors with verified genetic profile from European and US banks. Indicated for female couples, single women, or severe male factor.
See International Bank
Your path is unique. So is your plan.
We design a protocol tailored to you after understanding your story and your previous tests. No generic diagnoses or protocols.
The plan decides which services enter, not the catalog
Additional services are never offered as a generic package. Each one responds to a specific clinical indication that arises from the initial diagnosis: woman's age, family genetic history, ovarian quality, number of previous attempts, male factor, hereditary transmission risk.
After the First Consultation the team tells you which services add real value to your case and which would be unnecessary spending. That clinical honesty is part of the TripleMed™ model: we integrate only what the case needs.
Frequently asked questions about Additional Services
Do these services replace the main treatment?
No. They are complementary. They add to IVF, ICSI, PICSI or whichever treatment your case requires. Their function is to add precision, information, or resources that the standard treatment does not offer by itself.
How is it decided which ones to apply?
From the diagnosis. At the First Consultation the team reviews age, history, studies, and previous cases. Only services with clinical evidence supporting a real benefit for your situation are recommended.
Are PGT-A and PGT-M the same?
No. PGT-A detects alterations in chromosome number (aneuploidies). PGT-M detects a specific genetic mutation linked to a known hereditary disease in the family. They can be combined if the case justifies it.
Who is a candidate for Eligender™?
Eligender™ is indicated for couples with genetic diseases linked to sex chromosomes, and also available by informed family choice. Effectiveness is around 99%.
What makes Clarix™ different from traditional prenatal studies?
Clarix™ is non-invasive: it is done with a maternal blood sample. It requires no amniocentesis or chorionic villus biopsy. It detects the main chromosomal alterations with very high precision and no risk to the baby.
Is the International Sperm Bank different from the local donor?
Yes. The international bank gathers donors from Europe and the US with verified genetic profiles and broad catalogs. Useful when the couple looks for specific traits, a particular genetic profile, or when there is no local match available.
Does your case need something beyond a standard treatment?
Additional services join your plan when the diagnosis justifies it. We explain which ones apply to your case at the First Consultation.
Contact us